Department of Oral and Maxillofacial Surgery, TU Teaching Hospital, Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal.
Ek Ek Paila Foundation, Kathmandu, Nepal.
Br J Oral Maxillofac Surg. 2022 Jul;60(6):746-754. doi: 10.1016/j.bjoms.2022.02.001. Epub 2022 Feb 17.
Odontogenic keratocyst (OKC) is known for its benign but aggressive clinical behaviour, and presents a challenge in its management due to high recurrence rate following surgical intervention. The sourcing of Carnoy's solution, the widely used adjunct in OKC treatment, has lately become difficult especially after its banning by the United States Food and Drugs Agency (FDA). This has generated interest in exploring alternative chemical agents such as 5-Fluorouracil (5-FU) and Modified Carnoy's solution (MCS). We conducted a systematic review and meta-analysis to assess the effectiveness of 5-FU as an adjunct following surgical intervention of OKC. A protocol was registered in PROSPERO prior to the literature search. All studies reporting the use of 5-FU in OKC treatment were included in the initial search of multiple literature databases. Of the 148 initially identified articles, three met the criteria for the final appraisal. The relevant data were extracted and a meta-analysis was undertaken in relation to recurrence rate and nerve paraesthesia. There were no recurrence observed in cases treated with 5-FU (n=56), and the incidence of nerve paraesthesia was 20% (none permanent). This systematic review has revealed early encouraging results for 5-FU as an adjunct, however a caution is recommended due to overall low quality of evidence related to individual studies. We present the cumulative evidence on the effectiveness of 5-FU in OKC treatment with discussion on its mechanism of action, safety profile, application protocol, and the implications for clinical practice.
牙源性角化囊肿(OKC)以其良性但侵袭性的临床行为而闻名,由于手术后复发率高,其治疗具有挑战性。作为 OKC 治疗中广泛使用的辅助剂的 Carnoy 溶液的来源最近变得困难,尤其是在美国食品和药物管理局(FDA)禁止使用后。这引发了人们对探索替代化学剂(如 5-氟尿嘧啶(5-FU)和改良 Carnoy 溶液(MCS))的兴趣。我们进行了系统评价和荟萃分析,以评估 5-FU 在 OKC 手术后作为辅助治疗的有效性。在文献检索之前,已在 PROSPERO 中注册了一项方案。所有报告使用 5-FU 治疗 OKC 的研究均包括在多个文献数据库的初始搜索中。在最初确定的 148 篇文章中,有 3 篇符合最终评估标准。提取相关数据并进行荟萃分析,以评估复发率和神经感觉异常。用 5-FU 治疗的病例(n=56)未观察到复发,神经感觉异常的发生率为 20%(无永久性)。这项系统评价显示,5-FU 作为辅助剂具有早期令人鼓舞的结果,但由于与个别研究相关的证据总体质量较低,因此建议谨慎使用。我们介绍了 5-FU 在 OKC 治疗中的有效性累积证据,并讨论了其作用机制、安全性概况、应用方案以及对临床实践的影响。